Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures

Journal of Epilepsy

Volumn 11, Issue 5, 1998, Pages 248-255

  Schachter, Steven C ^a,d   Cahill, William T ^b   Wannamaker, Braxton B ^c   Shu, Vincent S ^e   Sommerville, Kenneth W ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c Carolina Neurological Clinic   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NONE

Author keywords

Administration and dosage; Complex partial epilepsy; Drug tolerance; GABA antagonists; Tiagabine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; VALPROIC ACID;

ADULT; AMNESIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; NERVOUSNESS; PRIORITY JOURNAL; SOMNOLENCE; THOUGHT DISORDER; VERTIGO;

EID: 0032170041     PISSN: 08966974     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6974(98)00024-3     Document Type: Article

References (13)

1. 1. Juul-Jensen P, Foldsprang A. Natural history of epileptic seizures. Epilepsia 1983;24:297-312.
2. 2. Sussman N, Heydorn WE. New and investigational antiepilepsy drugs. Expert Opin Invest Drugs 1994;3:355-68.
3. 3. Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N[4,4-bis(3-methyl-2-thienyl)but-3-en-l-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem 1990;54:639-47.
4. 4. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-26.
5. 5. Uthman B, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;5556-62.
6. 6. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled study. Epilepsy Res 1995;21:37-42.
7. 7. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995;36(Suppl 6):S14-S21.
8. 8. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: A dose frequency study. Arch Neurol 1997;54:595-601.
9. 9. Gustavson LE, Chu SY. High-performance liquid Chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr 1992;574:313-8.
10. 10. SAS/STAT user's guide: Version 6, fourth edition. Cary: SAS Institute, Inc., 1990.
11. 11. FDA, Department of Health and Human Services. COSTART. Center for Drugs and Biologies, Division of Drug and Biological Product Experience, Rockville, MD. 1993.
12. 12. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
13. 13. Leppik IE. Tiagabine: The safety landscape. Epilepsia 1995; 36(Suppl 6):S10-S13.